These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24882577)

  • 1. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
    Elias D; Vever H; Lænkholm AV; Gjerstorff MF; Yde CW; Lykkesfeldt AE; Ditzel HJ
    Oncogene; 2015 Apr; 34(15):1919-27. PubMed ID: 24882577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
    Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
    Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ
    Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
    Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
    Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Jan R; Huang M; Lewis-Wambi J
    Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered radiation responses of breast cancer cells resistant to hormonal therapy.
    Luzhna L; Lykkesfeldt AE; Kovalchuk O
    Oncotarget; 2015 Jan; 6(3):1678-94. PubMed ID: 25682200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
    Wu X; Zahari MS; Renuse S; Nirujogi RS; Kim MS; Manda SS; Stearns V; Gabrielson E; Sukumar S; Pandey A
    Mol Cell Proteomics; 2015 Nov; 14(11):2887-900. PubMed ID: 26330541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
    Maraqa L; Cummings M; Peter MB; Shaaban AM; Horgan K; Hanby AM; Speirs V
    Clin Cancer Res; 2008 Jan; 14(2):405-11. PubMed ID: 18223215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
    Ren YQ; Wang HJ; Zhang YQ; Liu YB
    Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
    Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
    Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
    Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
    BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
    Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
    BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells.
    Liu X; Miao W; Huang M; Li L; Dai X; Wang Y
    Mol Cell Proteomics; 2019 Nov; 18(11):2273-2284. PubMed ID: 31519767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.